There are many problems linked to oral drug administration including first pass metabolism, gastrointestinal tract damage and low levels of drug reaching the target site.
14th February 2018
General News
18th December 2017
The Journal of Pharmaceutical Innovation, Springer, has published the research paper 'Transdermal Delivery of Ibuprofen Utilizing a Novel Solvent-Free Pressure-sensitive Adhesive (PSA): TEPI® Technology'
General News
11th December 2017
Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance coming from other existing shareholders as well as new private investors. This latest investment will support the company as it progresses its ibuprofen TEPI Patch® into clinical development in early 2018.
Press Releases
17th November 2017
Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwickshire which have achieved success for themselves, their staff and their customers.
Press Releases
27th September 2017
Medherant, a leader in next-generation transdermal drug delivery, has signed an agreement with a Japanese transdermal patch company (“the company”), one of the world’s largest patch developers and manufacturers, to evaluate the potential of its TEPI Patch®
Press Releases
28th July 2017
Medherant is looking for an experienced CPM to manage its international clinical studies and support the Head of Clinical Development in establishing and maintaining a GCP management system.
General News
26th June 2017
Medherant Ltd, a University of Warwick spin-out company developing a next-generation transdermal drug delivery patch technology, is pleased to announce the appointment of two new senior executives, Sally Waterman and Angus Hone. These appointments mark a significant expansion of the Company’s management team to support the business as it moves into clinical development and commercialisation of its ibuprofen TEPI Patch®.
Press Releases
12th June 2017
Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has been chosen as one of 40 companies shortlisted for the Royal Society of Chemistry (RSC) Emerging Technologies Competition 2017.
Press Releases
6th June 2017
Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Sheryl Caswell as Head of Clinical Development.
Press Releases
8th May 2017
Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has appointed Laboratoires Plasto Santé to manufacture its first drug delivery patches.
Press Releases